Waters Strengthens Clinical Diagnostics with Xevo XR Innovation
MILFORD, Mass., July 27, 2026 Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its...
Genetic Disorders
Advertisement
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
BridgeBio Announces FDA Acceptance of Encaleret NDA for ADH1
PALO ALTO, Calif., July 22, 2026 BridgeBio has reached a significant regulatory milestone after the U.S. Food and Drug...
Mighty Therapeutics Announces New Era in Mitochondrial Medicine
BOSTON, June 22, 2026 Mighty Therapeutics, formerly known as Stealth BioTherapeutics, has officially announced its corporate rebranding, marking a...
CTAD and ADDF Unite to Accelerate Alzheimer’s Innovation
NEW YORK, N.Y., June 16, 2026 The Clinical Trials on Alzheimer’s Disease (CTAD) Conference and the Alzheimer’s Drug Discovery...
Advertisements
UCB Reports Positive KYGEVVI Outcomes in TK2d Patients
BRUSSELS, Belgium, June 17, 2026 UCB has announced the publication of two significant peer-reviewed studies in Brain Communications demonstrating...
Argo Biopharma Reports Positive Phase 2 HAE Data for BW-20805
SHANGHAI, China & NEW YORK, USA – June 8, 2026 Argo Biopharma has announced positive updated Phase 2 results...
Chiesi Wins EU Approval for Pediatric LOJUXTA Use
PARMA, Italy, June 5, 2026 Chiesi Global Rare Diseases has announced a major regulatory milestone following the European Commission’s...
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Resverlogix Appoints Bradley Glass to Strengthen Board Governance
Calgary, Alberta — November 18, 2025 — Resverlogix Corp. (TSX: RVX), a late-stage biotechnology firm specializing in epigenetic therapies,...
Advertisement
